Educational Crossmatching Scheme

Dispatched on the 19th July 2022

Summary of Results

A total of 33 reports were received, but not all labs reported results for all tests.

Consensus HLA Type of whole blood donor sample EDXM 01/2022:

	A *	B *	C*	DRB1*	DRB3*	DQA1*	DQB1*	DPA1*	DPB1*
	01	37	06	03 (17)	01	01	02	01	04:01
	02	57	06	13	02	05	06	01	04:02
Number of reports	33	33	33	33	26	31	33	24	29
% Labs in consensus	100%	100%	100%	100%	88%	100%	100%	100%	97%

There were a number of errors noted when defining the genotype.

Of the 26 participants that reported a genotype at DRB3, 23 (88%) reported DRB3*01, DRB3*02. However, 2 participants (8%) reported DRB3*01, DRB3*- and 1 participant reported DRB3*02:02, DRB3*03:03. Of the 29 participants that reported a genotype at DPB1, 28 (97%) reported DPB1*04:01, DPB1*04:02. However, 1 participant (3%) reported DPB1*04:01, DPB1*04:01/10.

EDXM 01 Serum 1/2022 Results

HLA Antibody Detection and Definition

(Based on 75% Consensus)

		HLA Class I	No of labs	% consensus	HLA Class II	No of labs	% consensus
Detection	lgG	Positive	32/32	100%	No Consensus	13/32 Pos	41%
Dete	IgM	Negative	2/2	100%	No Consensus	1/2 Pos	50%
	Total Number of Specificities Reported (by ≥ 1 lab, >1,000 MFI)	32			6		
	Number of Specificities Absent (reported by < 5% labs)	57			40		
on ¹	Number of Specificities Present (reported by ≥ 75% labs)	16			0		
Definition ¹	MFI >10000	Cw2, Cw4, Cw5, Cw6, Cw12, Cw15, Cw18		100%	N/A		N/A
	MFI 5000 - 9999	B63, Cw1, Cw9, Cw10, Cw14, Cw16, Cw17	33	91-100%	N/A	33	N/A
	MFI 2000 - 4999	B49, Cw7, Cw8		64-100%	N/A		N/A
	MFI 1000-1999			N/A	N/A		N/A

¹ 75% consensus 'present' specificities are displayed within the MFI value range reported by the **majority** of participants. Class I specificities n=89, Class II specificities n=46.

Crossmatching (Based on 75% Consensus)

	CDC							tometry
	PBL	-	T Cel	ls	B Cel	ls		B Cells
	Without DTT	With DTT	Without DTT	With DTT	Without DTT	With DTT	ith DTT T Cells	
	Negative	Negative	Negative	Negative	No Consensus	Negative	Positive	Positive
Number of reports	4/5	4/4	15/15	14/14	6/12 Neg	10/13	27/28	22/26
% Labs in consensus	80%	100%	100%	100%	50%	77%	96%	85%

Interpretation

Identification of Donor Specific Antibodies:

Specificity	No of Participants (n=33)	MFI Range Reported
Cw6	33 (100%)	11088-27000
B57	23 (70%)	657-3036
DQ6	6 (18%)	900-3280
B37	1 (3%)	1298
DRB3*01:01 (IgM)	1 (3%)	6680

Crossmatch interpretation:

	The most common responses included:						
Interpretation based on results	 CDC crossmatch negative Flow cytometry crossmatch positive Patient has Class I donor specific antibodies 						
Assigned risk	Medium $n = 6$ (19%)High $n = 12$ (37%)Contraindication $n = 14$ (44%)						
Immunological advice	 Not suitable for direct transplantation Donor is homozygous Cw6 Consider de-sensitisation High risk of acute antibody mediated rejection If transplant proceeds use enhanced immunosuppression and post-transplant monitoring 						
If advice is not to transplant, recommendations for future transplants	 Seek alternative donor such as deceased donor or kidney sharing scheme Possible antibody removal pre-transplant Longitudinal antibody monitoring to assess potential delisting Investigate whether the patient is a suitable for a higher risk transplant Perform additional testing such as autologous crossmatching or antibody testing using additional kits 						

EDXM 01 Serum 2/2022 Results

HLA Antibody Detection and Definition

(Based on 75% Consensus)

		HLA Class I	No of labs	% consensus	HLA Class II	No of labs	% consensus
Detection	lgG	Negative	30/32	94%	Positive	32/32	100%
Dete	IgM	Negative	2/2	100%	Negative	2/2	100%
	Total Number of Specificities Reported (by ≥ 1 lab, >1,000 MFI)	3			21		
	Number of Specificities Absent (reported by < 5% labs)	86			25		
۲ ۲	Number of Specificities Present (reported by ≥ 75% labs)	0			17		
Definition ¹	MFI >10000	N/A		N/A	DR103, DR16, DR17, DR18, DR4, DR11, DR12, DR13, DR14, DR7, DR8, DR9, DR51, DR52		91-100%
	MFI 5000 - 9999	N/A	33	N/A	DR15, DQ6	33	97-100%
	MFI 2000 - 4999	N/A		N/A	DR10		100%
	MFI 1000-1999	N/A		N/A	N/A		N/A

¹ 75% consensus 'present' specificities are displayed within the MFI value range reported by the **majority** of participants. Class I specificities n=89, Class II specificities n=46.

Crossmatching Results (Based on 75% Consensus)

%

,	CDC							tometry	
	PBL		T Cells		B Cells		T Cells	B Cells	
	Without DTT	With DTT	Without DTT	With DTT	Without DTT	With DTT	I Cells	D Cells	
	No Consensus	No Consensus	Negative	Negative	Positive	Positive	Negative	Positive	
Number of reports	3/5 Pos	2/4 Pos	14/15	13/14	13/13	14/14	24/28	26/26	
Labs in consensus	60%	50%	93%	93%	100%	100%	86%	100%	

Interpretation

Identification of Donor Specific Antibodies:

Specificity	No of Participants (n=33)	MFI Range Reported
DR17	32 (97%)	11274-21451
DR13	32 (97%)	12419-30740
DQ6	29 (88%)	817-18504
DR52	27 (82%)	8402-22688
DQA1*05	1 (3%)	1503

Crossmatch interpretation:

	The most common responses included:						
Interpretation based on results	 CDC crossmatch B cell positive Flow cytometry crossmatch T cell negative, B cell positive Class II donor specific antibodies present 						
Assigned risk	Medium $n = 1$ (3%) High $n = 10$ (31%) Contraindication $n = 21$ (66%)						
Immunological advice	 Not suitable for direct transplantation Consider de-sensitisation High risk of hyperacute antibody mediated rejection If transplant proceeds use enhanced immunosuppression and post-transplant monitoring 						
If advice is not to transplant, recommendations for future transplants	 Seek alternative donor such as deceased donor or kidney sharing scheme Possible antibody removal pre-transplant Longitudinal antibody monitoring to access potential delisting Investigate whether the patient is a suitable for a higher risk transplant Perform additional testing such as autologous crossmatching or antibody testing using additional kits 						

EDXM 01 Serum 3/2022 Results

HLA Antibody Detection and Definition

(Based on 7	75% Consens	us)
-------------	-------------	-----

		HLA Class I	No of labs	% consensus	HLA Class II	No of labs	% consensus
Detection	lgG	Negative	27/31	87%	Negative	30/31	97%
Dete	lgM	No Consensus	1/2 Pos	50%	No Consensus	1/2 Pos	50%
	Total Number of Specificities Reported (by ≥ 1 lab, >1,000 MFI)	1			0		
	Number of Specificities Absent (reported by < 5% labs)	88			46		
ition ¹	Number of Specificities Present (reported by ≥ 75% labs)	0			0		
Definition ¹	MFI >10000	N/A		N/A	N/A		N/A
	MFI 5000 - 9999	N/A	22	N/A	N/A	22	N/A
	MFI 2000 - 4999	N/A	33	N/A	N/A	33	N/A
	MFI 1000-1999	N/A		N/A	N/A		N/A

¹75% consensus 'present' specificities are displayed within the MFI value range reported by the majority of participants. Class I specificities n=89, Class II specificities n=46.

Crossmatching (Based on 75% Consensus)

	CDC						Flow Cytometry	
	F	BL	T Ce	ells	B Cells			
	Without DTT	With DTT	TT Without With DTT		Without DTT	With DTT	T Cells	B Cells
	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Number of reports	5/5	4/4	15/15	14/14	11/13	14/14	28/28	26/26
% Labs in consensus	100%	100%	100%	100%	85%	100%	100%	100%

Interpretation

Identification of Donor Specific Antibodies:

Specificity	No of Participants (n=33)	MFI Range Reported
DQA1*05:01	1 (3%)	9481

Crossmatch interpretation:

	The most common responses included:	
Interpretation based on results	 Negative CDC crossmatch Negative Flow cytometry crossmatch No DSAs detected Patient has no detectable HLA antibodies 	
Assigned risk	Low/standard n = 32 (100%)	
Immunological advice	 Suitable for transplantation Standard immunosuppression and post-monitoring protocols Review match grade Confirm ABO compatibility 	
If advice is not to transplant, recommendations for future transplants	• N/A	